Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 17 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:13 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 1, 2024 | Feb 24, 2023 | Mar 14, 2022 | Mar 18, 2021 |
| Revenue | – | $0 | $0 | $0 | $0 |
| Operating expenses | $122.1M | $7.30M | $10.6M | $19.3M | $9.77M |
| Research and development | $100.6M | $1.01M | $4.75M | $13.8M | $4.99M |
| Selling, general and administrative | $21.4M | $6.28M | $5.85M | $5.50M | $4.77M |
| Operating income | -$122.1M | -$7.30M | -$10.6M | -$19.3M | -$9.77M |
| Interest expense | – | – | – | – | $9.00K |
| Income tax | – | $0 | $0 | – | -$9.00K |
| Net income | -$105.4M | -$5.34M | -$9.93M | -$19.3M | -$9.74M |
| EPS, basic | – | $-0.37 | $-0.69 | – | – |
| EPS, diluted | – | $-0.37 | $-0.69 | – | – |
| Weighted shares, basic | – | 14.4M | 14.4M | – | – |
| Weighted shares, diluted | – | 14.4M | 14.4M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 1, 2024 | Feb 24, 2023 | Mar 14, 2022 | Mar 18, 2021 |
| Cash and equivalents | $46.9M | $37.4M | $42.4M | $53.4M | $49.1M |
| Short-term investments | $290.1M | – | – | – | – |
| Total current assets | $343.9M | $37.6M | $42.7M | $54.4M | $50.0M |
| Property, plant and equipment | $288.0K | $10.0K | $25.0K | $48.0K | $21.0K |
| Total assets | $488.6M | $37.9M | $43.1M | $54.9M | $50.4M |
| Accounts payable | – | $362.0K | $334.0K | $1.12M | $1.77M |
| Total current liabilities | $15.4M | $637.0K | $1.13M | $3.50M | $3.50M |
| Total liabilities | $16.7M | $841.0K | $1.41M | $3.88M | $3.91M |
| Shareholders' equity | $471.9M | $37.0M | $41.7M | $51.0M | $46.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 1, 2024 | Feb 24, 2023 | Mar 14, 2022 | Mar 18, 2021 |
| Operating cash flow | -$88.2M | -$5.01M | -$10.9M | -$18.8M | -$7.72M |
| Capital expenditures | $209.0K | $0 | $2.00K | $43.0K | $19.0K |
| Free cash flow | -$88.4M | -$5.01M | -$10.9M | -$18.8M | -$7.74M |
| Depreciation and amortization | – | $15.0K | $20.0K | $16.0K | $8.00K |
| Stock-based compensation | $24.2M | $686.0K | $556.0K | $497.0K | $43.0K |
| Investing cash flow | -$96.7M | $0 | -$2.00K | -$43.0K | -$19.0K |
| Financing cash flow | $170.3M | $0 | – | $23.1M | $48.5M |
| Net change in cash | – | -$5.01M | -$10.9M | $4.29M | $40.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 67.8M | +40.1% | SEC |
| Jul 31, 2026 | 66.2M | +76.8% | SEC |
| Apr 30, 2026 | 60.3M | +61.1% | SEC |
| Feb 28, 2026 | 49.5M | +32.3% | SEC |
| Oct 31, 2025 | 48.4M | +38.3% | SEC |
| Jul 31, 2025 | 37.5M | +158.2% | SEC |
| Apr 30, 2025 | 37.4M | +158.1% | SEC |
| Feb 28, 2025 | 37.4M | +158.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.